Secondary endpoints include prostate specific antigen response rate, overall response rate (PCWG3 modified RECIST 1.1 criteria), PK, PD, immunogenicity, and biomarker analyses. Enrollment began in Dec 2020; as of 10 Feb 2022, 4 sites have been initiated and 23 patients enrolled; currently, dose escalation is ongoing.
over 2 years ago
P1 data • IO biomarker
|
AR (Androgen receptor) • KLK2 (Kallikrein-related peptidase 2)
Secondary endpoints include prostate specific antigen response rate, overall response rate (PCWG3 modified RECIST 1.1 criteria), PK, PD, immunogenicity, and biomarker analyses. Enrollment began in Dec 2020; as of Sep 2021, 4 sites have been initiated and 14 pts enrolled; currently, dose escalation is ongoing.
almost 3 years ago
P1 data • IO biomarker
|
AR (Androgen receptor) • KLK2 (Kallikrein-related peptidase 2)